Form 4: Organon & Co. Executive Reports Changes in Beneficial Ownership

Head of R&D & CMO, Juan Camilo Arjona Ferreira, reports transactions involving Organon & Co. stock, including the vesting of restricted stock units and the grant of stock options and additional RSUs.

Summary

• On March 31, 2025, Juan Camilo Arjona Ferreira, Head of R&D & CMO at Organon & Co., reported changes in beneficial ownership of the company's stock.
• These changes include the vesting of 8,865 Restricted Stock Units (RSUs), the disposal of 3,172 shares to cover tax obligations at a price of $14.51 per share, and the acquisition of 8,865 shares upon RSU vesting.
• Following these transactions, Arjona Ferreira directly owns 17,380.355 shares of Organon common stock.
• Additionally, Arjona Ferreira was granted 198,019 stock options exercisable in three equal installments starting March 31, 2026, and 40,295 RSUs vesting similarly.
• The price of Organon common stock on March 28, 2025, was $14.51.

Sentiment

Score: 6

Explanation: The document reflects standard executive compensation practices. It is neutral in tone and doesn't indicate any significant positive or negative developments for the company.

Positives

• The grant of stock options and RSUs to a key executive like the Head of R&D & CMO suggests the company's commitment to incentivizing and retaining top talent.
• The vesting of RSUs represents a form of compensation and aligns the executive's interests with those of the shareholders.

Negatives

• The disposal of shares to cover tax obligations, while a normal occurrence, slightly reduces the executive's direct holdings in the company.

Risks

• There are no specific risks explicitly mentioned in this document.
• However, any significant changes in ownership by key executives could be perceived as a potential risk if interpreted negatively by the market.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of stock options and RSUs extends to March 2028, indicating a long-term incentive structure for the executive.

Industry Context

Executive compensation through stock options and RSUs is a common practice in the pharmaceutical industry to align management's interests with shareholder value and encourage long-term growth. This filing reflects standard compensation practices.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the pharmaceutical industry, aligning executive incentives with shareholder value.
• Companies like Pfizer, Merck, and Johnson & Johnson also utilize similar equity-based compensation plans for their executives.
• The vesting schedules and grant sizes are generally benchmarked against peer companies to ensure competitiveness in attracting and retaining talent.

Stakeholder Impact

• The vesting of RSUs and granting of stock options can positively impact employee morale and retention.
• Shareholders may view the alignment of executive interests with long-term company performance favorably.

Key Dates

Keywords

Organon & Co., Beneficial Ownership, Form 4, Stock Options, Restricted Stock Units, RSU, OGN, Executive Compensation, Insider Trading